 |
|
|
 |
Frequency Of Attention-Deficit/Hyperactivity Disorder Is Approximately 7.5%
A new Mayo Clinic study shows that attention-deficit/hyperactivity disorder (AD/HD) affects up to
7.5 percent of school-age children. Previous studies had estimated the occurrence of AD/HD to be anywhere between one and
20 percent of school-age children. The Mayo Clinic report, published in the March issue of Archives of Pediatrics and
Adolescent Medicine, addresses the confusion about the number of children affected by AD/HD. more
|
|
Calcium And Phosphorus Co-Dependent For Bone Health
Healthy bones and soft tissues need both calcium and phosphorus to grow and develop throughout life.
Research presented at the National Osteoporosis Foundation Fifth International Symposium 9 March 2002 showed for the first
time that the nutrients are co-dependent in the health benefits associated with calcium in humans undergoing bone-building
therapy. more
|
|
|
|
Information For Patients: Calcium Supplement Guidelines
Calcium is an essential mineral found in great abundance in the body. Ninety-nine percent of all the
calcium in the body is found in the bones and teeth. The remaining one percent is in the blood. Calcium plays important roles in
nerve conduction, muscle contraction, and blood clotting. If calcium levels in the blood drop below normal, calcium will be
taken from bone and put into the blood in order to maintain blood calcium levels. Therefore, it is important to consume enough
calcium to maintain adequate blood and bone calcium levels. more
|
|
Multinational Study Will Examine The Safety And Efficacy Of Prolonged Administration Of Lovenox(R)
For Prophylaxis Of Blood Clots In Medical Patients With Restricted Mobility
A 5,800-patient clinical trial designed to evaluate the benefit of extended prophylaxis of venous
thromboembolism (VTE) in medical patients with restricted mobility was announced today by Aventis Pharmaceuticals, the U.S.
pharmaceutical business of Aventis Pharma AG. EXCLAIM (Extended CLinical prophylaxis in Acutely Ill Medical patients), a
multi-center international study, will compare extended use of Lovenox ® (enoxaparin sodium) Injection, a
low-molecular-weight heparin, to placebo for the prophylaxis of blood clots. more
|
|
Prescribing Information: Lovenox
The number one selling low-molecular-weight heparin in the world, Lovenox was approved in the U.S.
and Canada in 1993. It has been available in Europe since 1987 and is known under the brand names Lovenox, Clexane and
Klexane. Get the full prescribing information in today's issue of Vidyya. more
|
|
|
